tax rate still shock increas tp
tax rate strong perform deliv dramat upsid
updat model follow friday earn
updat guidanc guidanc punctuat
effect tax rate also deliv anoth strong quarter
underli perform half yoy earn growth
current estim come oper growth
oppos tax benefit also opportun discuss result
guidanc cfo follow discuss make
numer revis model ep estim
increas meaning
new target price increas suggest
addit upsid friday close blue sky valuat
grey sky valuat suggest risk/reward fairli
balanc upsid risk view includ stronger expect
humira growth unexpect pipelin success downsid risk
includ humira erod faster expect disappoint clinic data
especi rova-t pleas let us know would like updat
valuat target price blend dcf rel
price-to-earnings valuat dcf base cash flow forecast
wacc termin growth price-to-earnings valuat
base ep iron price-to-earnings multipl
even friday move remain base latest close
price midpoint compani new ep guidanc rang
exactli multipl trade prior
earn base compani previou guidanc
would expect addit multipl expans given
compani near-term outlook comment around like plan
increas cash return sharehold near futur
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
notabl model updat make sever chang compani model
follow result updat guidanc follow call
cfo notabl increas mavyret hcv sale
reflect strong uptak product sinc launch last year also
increas near-term humira sale estim yoy
growth vs compani guidanc approach
declin start still remain last year
model make smaller adjust product imbruvica venclexta
slightli lower us increas ex-u base report sale trend
sale estim differ compani expect certain pipelin
asset elagolix upadacitinib risankizumab rova-t
obtain probability-adjust sale adjust model
assum product obtain sale
dcf would increas make rel modest adjust gross margin
oper expens align close compani guidanc
biggest swing come significantli lower tax rate base compani
new expect follow passag us tax cut job act tax
rate come gradual increas
maintain level go forward tax rate chang alon account
increas dcf way account move
saw stock
follow-up manag
opportun speak cfo member
team follow confer call gain addit clariti dynam
around certain product well bake expect
around fy summar compani answer question
detail tax
tax rate straight line next year
mani product tax advantag locat highli effici tax
structur big motiv behind tri invers old tax system
tax reform use ireland low-tax countri result
pay averag underli tax rate
would repatri money back use us dividend etc would
increas effect tax rate
need repatri tax rate close minimum
specif tax credit contribut bring
time product mix sale come imbruvica increas
us profit act rais tax rate slowli
one time charg
full year howev factor bring tax rate even
provis base eros anti-abus tax elimin profit reduct
inter-compani royalti dont appli inventori physic move
countri use transfer price royalti
charl martineau pm univers toronto cs believ function similar must technic differ
view co-pay accumul program
new phenomenon link high deduct plan
compani say huge piec busi concern element
believ patient get big surpris sign high deduct
impact program factor guidanc
hope lead patient rethink plan dont think there
good line sight patient right
industri lot idea counter
impact seen late first quarter/earli second quarter
humira medicar low percentag medicaid rest commerci
specialist primari care
anyth done off-set impact
earli say anyth
constantli look asset
look late-stag pipelin opportun indic expans
believ attract pipelin industri
burn platform need acquir asset
isnt compel need compani deal mani thing
probabl best time
look earlier stage asset singl asset build pipelin
find anyth time-frame even neuro readout
would necessarili feel need wait
go market strategi women health
lupron sell market endometriosi
greater footprint requir physician detail overal salesforc
familiar diseas therapeut area doctor
elagolix specialist product primari care
focu cystic fibrosi
earli big part busi today
think peopl arent appreci later stage asset yet need
talk even earlier one
dynam around ex-u humira growth face
expect ex-u humira sale
expect flat oper fx benefit month fourth quarter
biosimilar competit kick see pronounc effect
take proactiv measur set contract sustain volum
ahead patent expiri like lead price pressur
us million unless otherwis state
us million unless otherwis state
us million unless otherwis state
research-bas pharmaceut compani broad
sustain portfolio market-lead proprietari
pharmaceut biolog sold world-wide
price jan rate neutral target price analyst vamil divan
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
cash-flow financ activ
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
 close
blue sky valuat base greater sale
humira imbruvica market product compar
current base case assumpt blue sky valuat base
dcf driven wacc termin valu
grey sky valuat base lower sale humira
imbruvica market product compar current base
case assumpt grey sky valuat base dcf driven
wacc termin valu
compani mention price
